Holen Sie sich die Stockscreener-App
194.38
6.00%
11.00
Handel nachbörslich:
194.38
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$183.38
Offen:
$183.12
24-Stunden-Volumen:
2.44M
Relative Volume:
1.98
Marktkapitalisierung:
$28.53B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
22.07
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+2.27%
1M Leistung:
+5.73%
6M Leistung:
+31.46%
1J Leistung:
+61.75%
1-Tages-Spanne:
$180.18
$195.89
1-Wochen-Bereich:
$179.15
$195.89
52-Wochen-Spanne:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
194.38 | 26.91B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
851.25 | 780.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.35 | 548.34B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
203.89 | 349.67B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
185.20 | 289.51B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
111.02 | 271.76B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
BofA raises Biogen stock price target on solid quarterly results By Investing.com - Investing.com Canada
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Biogen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen Q1 Earnings Call Highlights - Yahoo Finance
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs - Yahoo Finance
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge - TechStock²
Earnings call transcript: Biogen Q1 2026 beats expectations with strong EPS and revenue growth - Investing.com
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus
Biogen (BIIB) Projects Revenue Decline and Adjusts EPS Forecast for 2026 - GuruFocus
Biogen cuts annual profit forecast on acquisition-related charges - Reuters
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Biogen Q1 Non-GAAP Earnings, Revenue Rise; Cuts 2026 Earnings Outlook - marketscreener.com
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Biogen posts Q1 beat, trims earnings outlook (BIIB:NASDAQ) - Seeking Alpha
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales - Yahoo Finance
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Biogen : BIIB Q1 26 Earnings Presentation Final - marketscreener.com
Biogen posts Q1 revenue of $2.5B, surpasses estimates - Breakingthenews.net
Biogen Sales Beat Estimates as Alzheimer’s Drug Gains Momentum - Bloomberg.com
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Eyes on Asia: Takesa, Daiichi Sankyo, Biogen - BioXconomy
Is Biogen (BIIB) Still Attractive After Recent Share Price Rebound And DCF Upside Estimate - simplywall.st
Truist reiterates Hold on Biogen stock ahead of tau therapy data - Investing.com Australia
Biogen is entitled to damages in Tecfidera case rules Regional Court Hamburg - JUVE Patent
Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts - Yahoo Finance
Emerging Sub-Segments Transforming the Avonex Market Landscape - openPR.com
Apellis surges on $5.6B buyout deal with Biogen - MSN
AEGON ASSET MANAGEMENT UK Plc Raises Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Buyout Bet On Felzartamab: A Hidden Blockbuster In The Making? - Smartkarma
The Goldman Sachs Group Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $21.83 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Should Biogen’s (BIIB) Full Global Control of Felzartamab Require Action From Investors? - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
BofA raises Biogen stock price target to $200 on base business - Investing.com
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal - Yahoo Finance
Goldman Sachs Adjusts Price Target on Biogen to $238 From $231, Maintains Buy Rating - marketscreener.com
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - Yahoo Finance
Wolfe Research Has Bearish Forecast for Biogen Q2 Earnings - MarketBeat
Biogen Inc. $BIIB Shares Bought by B. Metzler seel. Sohn & Co. AG - MarketBeat
Postpartum Depression Market is projected to Hit USD 93.6 - openPR.com
Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN
Analysts estimate Biogen Inc. (BIIB) to report a decline in earnings: What to look out for - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
APLS stock soars 140% today – here’s everything to know about its massive $5.6B deal with Biogen - MSN
Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention - simplywall.st
JPMorgan Adjusts Price Target on Biogen to $185 From $175, Maintains Neutral Rating - marketscreener.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):